Therefore, some molecular inhibitors targeting FABP4 might block its function and bring a promising future for ovarian cancer therapy, such as BMS309403, which was initially used to treat atherosclerosis and type 2 diabetes and has been proven to increase platinum‐based drug sensitivity in vivo.13, 33, 34. The gene discussed is FABP4; the disease is ovarian carcinoma.